Oruka Therapeutics Statistics
Total Valuation
ORKA has a market cap or net worth of $5.92 billion. The enterprise value is $5.42 billion.
| Market Cap | 5.92B |
| Enterprise Value | 5.42B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORKA has 60.31 million shares outstanding. The number of shares has increased by 85.49% in one year.
| Current Share Class | 60.31M |
| Shares Outstanding | 60.31M |
| Shares Change (YoY) | +85.49% |
| Shares Change (QoQ) | +1.38% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 78.18% |
| Float | 51.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.18 |
| P/TBV Ratio | 12.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.76, with a Debt / Equity ratio of 0.00.
| Current Ratio | 23.76 |
| Quick Ratio | 23.38 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.31% and return on invested capital (ROIC) is -19.52%.
| Return on Equity (ROE) | -27.31% |
| Return on Assets (ROA) | -18.91% |
| Return on Invested Capital (ROIC) | -19.52% |
| Return on Capital Employed (ROCE) | -27.34% |
| Weighted Average Cost of Capital (WACC) | 3.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +621.54% in the last 52 weeks. The beta is -0.16, so ORKA's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | +621.54% |
| 50-Day Moving Average | 79.43 |
| 200-Day Moving Average | 49.70 |
| Relative Strength Index (RSI) | 63.24 |
| Average Volume (20 Days) | 887,310 |
Short Selling Information
The latest short interest is 8.83 million, so 14.65% of the outstanding shares have been sold short.
| Short Interest | 8.83M |
| Short Previous Month | 9.16M |
| Short % of Shares Out | 14.65% |
| Short % of Float | 17.29% |
| Short Ratio (days to cover) | 4.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -133.40M |
| Pretax Income | -116.25M |
| Net Income | -94.19M |
| EBITDA | -133.38M |
| EBIT | -133.40M |
| Earnings Per Share (EPS) | -$1.92 |
Balance Sheet
The company has $388.83 million in cash and $1.81 million in debt, with a net cash position of $494.15 million or $8.19 per share.
| Cash & Cash Equivalents | 388.83M |
| Total Debt | 1.81M |
| Net Cash | 494.15M |
| Net Cash Per Share | $8.19 |
| Equity (Book Value) | 486.72M |
| Book Value Per Share | 9.64 |
| Working Capital | 378.62M |
Cash Flow
In the last 12 months, operating cash flow was -$90.92 million and capital expenditures -$269,000, giving a free cash flow of -$91.19 million.
| Operating Cash Flow | -90.92M |
| Capital Expenditures | -269,000 |
| Depreciation & Amortization | 110,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -91.19M |
| FCF Per Share | -$1.51 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORKA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -85.49% |
| Shareholder Yield | -85.49% |
| Earnings Yield | -1.59% |
| FCF Yield | -1.54% |
Analyst Forecast
The average price target for ORKA is $148.17, which is 50.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $148.17 |
| Price Target Difference | 50.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 3, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Sep 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |